Latest On Recro Pharma, Inc (REPH):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-03-02 05:43 EST | News | Recro Pharma GAAP EPS of -$0.04 beats by $0.03, revenue of $22.3M beats by $0.89M | N/A |  |
| 2022-03-02 05:43 EST | News | Recro Pharma GAAP EPS of $0.04 beats by $0.11, revenue of $22.3M beats by $0.89M | N/A | |
| 2022-03-02 05:43 EST | News | Recro Pharma, Inc. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-02 05:43 EST | News | Recro Pharma, Inc. (REPH) CEO David Enloe On Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-28 17:39 EST | News | Recro Pharma Q4 2021 Earnings Preview | N/A | |
About Recro Pharma, Inc (REPH):
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.
General
- Name Recro Pharma, Inc
- Symbol REPH
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 185
- Last Split Factor1115:1000
- Last Split Date2019-11-22
- Fiscal Year EndDecember
- IPO Date2014-03-07
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryBiotechnology
- Web URLhttp://www.recrogainesville.com
View More
Valuation
- Trailing PE 35.15
- Forward PE 18.25
- Price/Sales (Trailing 12 Mt.) 1.35
- Enterprise Value Revenue 3.17
- Enterprise Value EBITDA 1029.41
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.58
- Next Year EPS Estimate -$0.18
- Next Quarter EPS Estimate -$0.18
- Profit Margin -41%
- Operating Margin -13%
- Return on Assets -5%
- Revenue 66.5 million
- Earnings Per Share -$2.75
- Revenue Per Share $2.8
- Gross Profit 12.37 million
- Quarterly Earnings Growth -43.8%
View More
Highlights
- Market Capitalization 121.23 million
- EBITDA 205000
- Analyst Target Price $5.5
- Book Value Per Share -$0.84
View More
Share Statistics
- Shares Outstanding 33.21 million
- Shares Float 28.34 million
- % Held by Insiders 240%
- % Held by Institutions 79.63%
- Shares Short 1.26 million
- Shares Short Prior Month 1.34 million
- Short Ratio 1.63
- Short % of Float 4%
- Short % of Shares Outstanding 4%
View More
Technicals
- Beta 1.16
- 52 Week High $9.19
- 52 Week Low $1.49
- 50 Day Moving Average 3.91
- 200 Day Moving Average 2.78
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Recro Pharma, Inc (REPH) Dividend Calendar:
Recro Pharma, Inc (REPH) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Recro Pharma, Inc (REPH) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | N/A |
| Income Before Tax | -11.67 million | N/A | N/A | -7.69 million | N/A |
| Selling General Administrative | 4 million | N/A | N/A | 5.45 million | N/A |
| Gross Profit | -2.59 million | N/A | N/A | 3.52 million | N/A |
| Ebit | -7.27 million | N/A | N/A | -393000 | N/A |
| Operating Income | -7.24 million | N/A | N/A | -2.57 million | N/A |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | 9.91 million | N/A | N/A | 21.78 million | N/A |
| Cost of Revenue | 12.51 million | N/A | N/A | 18.25 million | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | N/A |
| Net Income From Continuing Operations | -11.67 million | N/A | N/A | -7.69 million | N/A |
| Net Income Applicable to Common Shares | -11.67 million | -2.13 million | -6.01 million | N/A | N/A |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -3.21 million | N/A | -620000 | N/A | N/A |
| Change to Liabilities | 397000 | -1.92 million | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | -3.21 million | -1.62 million | N/A | N/A | N/A |
| Net Borrowings | N/A | 3.32 million | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | -82000 | N/A | -1.02 million | N/A | N/A |
| Change to Operating Activities | 468000 | -1.28 million | N/A | N/A | N/A |
| Change in Cash | N/A | N/A | 1.9 million | N/A | N/A |
| Total Cash from Operating Activities | 1.99 million | 868000 | 2.37 million | N/A | N/A |
| Depreciation | 2.22 million | N/A | 2.15 million | N/A | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | 192000 | N/A | 3.03 million | N/A | N/A |
| Change to Account Receivables | -2.05 million | N/A | -97000 | N/A | N/A |
| Other Cash Flow from Financing Activities | -78000 | N/A | N/A | N/A | N/A |
| Change to Net Income | 3.71 million | 3.91 million | N/A | N/A | N/A |
| Capital Expenditures | 3.21 million | N/A | 620000 | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 117.52 million | 123.7 million | N/A | 119.11 million | 117.17 million |
| Total Stockholder Equity | -14.1 million | -15.13 million | N/A | -12.19 million | -6.71 million |
| Other Current Liabilities | N/A | 2.65 million | N/A | N/A | 2.39 million |
| Total Assets | 103.42 million | 108.57 million | N/A | 106.92 million | 110.46 million |
| Common Stock | 286000 | 236000 | 236000 | N/A | 233000 |
| Other Current Assets | 9.66 million | N/A | N/A | N/A | N/A |
| Retained Earnings | -234.38 million | -222.71 million | -220.59 million | -214.58 million | -206.88 million |
| Other Liabilities | 1.62 million | N/A | 313000 | N/A | N/A |
| Other Assets | 486000 | 503000 | 399000 | N/A | N/A |
| Cash | 23.76 million | 21.49 million | N/A | 19.87 million | 19.15 million |
| Total Current Liabilities | 7.8 million | 14.92 million | N/A | 9.41 million | 6.49 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 43.84 million | 43.48 million | 42.45 million | N/A | 42.7 million |
| Total Current Assets | 54.07 million | 58.92 million | N/A | 57.78 million | 60.16 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -19.12 million | -20.8 million | -21.72 million | N/A | -14.31 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | 108.1 million | 108.4 million | N/A | 108.78 million | 110.32 million |
| Inventory | 11.61 million | 11.58 million | N/A | 12.04 million | 15.07 million |
| Accounts Payable | 6.33 million | 657000 | N/A | 1.14 million | 989000 |
Recro Pharma, Inc (REPH) Chart:
Recro Pharma, Inc (REPH) News:
Below you will find a list of latest news for Recro Pharma, Inc (REPH) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Recro Pharma, Inc (REPH) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest REPH Trades:
Recro Pharma, Inc (REPH) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-09-22 | 8-K (Current report) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-30 | 8-K (Current report) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-15 | 8-K (Current report) | |
| 2020-05-12 | 8-K (Current report) | |
| 2020-05-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-11 | 8-K (Current report) | |
| 2020-05-11 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-05-01 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-04-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-20 | 4/A (Statement of changes in beneficial ownership of securities) | |
Recro Pharma, Inc (REPH) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Recro Pharma, Inc (REPH). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 240%
Institutional Ownership: 7963%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-06-05 | Ryan David Lake | Chief Financial Officer | Buy | 2,500.00 | 61,238.00 | | ||
| 2020-05-07 | Arnaud Ajdler | Director | Buy | 8,363.00 | 23,757.00 | | ||
| 2020-05-07 | Bryan M. Reasons | Director | Buy | 8,363.00 | 40,506.00 | | ||
| 2020-05-07 | Michael Berelowitz | Director | Buy | 8,363.00 | 49,623.00 | | ||
| 2020-05-07 | WINSTON J CHURCHILL | Director | Buy | 8,363.00 | 51,059.00 | | ||
| 2020-05-07 | William Ashton | Director | Buy | 8,363.00 | 53,357.00 | | ||
| 2020-05-07 | Wayne Weisman | Director | Buy | 8,363.00 | 58,059.00 | | ||
| 2020-04-17 | GERALDINE HENWOOD | President and CEO | Sell | 80,000.00 | 8.22 | 657,600.00 | 161,194.00 | |
| 2020-02-03 | Ryan David Lake | Chief Financial Officer | Buy | 12,000.00 | 58,738.00 | | ||
| 2020-01-18 | GERALDINE HENWOOD | President and CEO | Buy | 5,000.00 | 246,746.00 | | ||
| 2019-12-05 | Arnaud Ajdler | Director | Buy | 7,439.00 | 15,394.00 | | ||
| 2019-12-05 | GERALDINE HENWOOD | President and CEO | Buy | 93,550.00 | 246,691.00 | | ||
| 2019-12-05 | Bryan M. Reasons | Director | Buy | 9,156.00 | 32,143.00 | | ||
| 2019-12-05 | Karen Flynn | Director | Buy | 11,071.00 | 39,283.00 | | ||
| 2019-12-05 | Michael Berelowitz | Director | Buy | 13,848.00 | 41,260.00 | | ||
| 2019-12-05 | WINSTON J CHURCHILL | Director | Buy | 15,284.00 | 42,696.00 | | ||
| 2019-12-05 | ALFRED ALTOMARI | Director | Buy | 15,284.00 | 44,196.00 | | ||
| 2019-12-05 | William Ashton | Director | Buy | 17,582.00 | 44,994.00 | | ||
| 2019-12-05 | Ryan David Lake | Chief Financial Officer | Buy | 17,283.00 | 48,812.00 | | ||
| 2019-12-05 | Wayne Weisman | Director | Buy | 15,284.00 | 49,696.00 | |